Yayınlar & Eserler

Yayın Ağı
Makaleler 24
Tümü (24)
SCI-E, SSCI, AHCI (18)
SCI-E, SSCI, AHCI, ESCI (20)
ESCI (2)
Scopus (20)
TRDizin (4)

1. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint Inhibitors

Şahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.
Journal of Oncological Science , cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin) Creative Commons License identifier

2. Prognostic significance of ductal carcinoma in situ coexisting with invasive ductal carcinoma: Biological behavior, immune response and survival outcomes

Fedai N. K., Koc I., KAVGACI G., ÜNER M., ÜNER A., AKSOY S., et al.
Molecular and Clinical Oncology , cilt.24, sa.1, 2026 (ESCI, Scopus) identifier identifier

3. Breast Radiotherapy: A Potential Risk Factor for Resistant Clone Development in Patients with Brain Metastasis

Yildirim H. c., Kavgacı G., Evlendi Y., CHALABIYEV E., Guven D. C., Dizdar O., et al.
Journal of oncological sciences , cilt.11, sa.1, ss.7-13, 2025 (TRDizin) identifier

4. Evaluation of the Effect of Radiotherapy Timing on Toxicity in HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine During the Adjuvant Period

Deliktaş İ., Kinikoglu O., Kavgacı G., Kuzu Ö. F., tuylu T. B., ateş ö., et al.
Acta haematologica oncologica Turcica , cilt.58, sa.1, ss.12-15, 2025 (TRDizin) Creative Commons License identifier

5. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , sa.4, ss.129-137, 2025 (SCI-Expanded) identifier identifier

6. Sequential immunotherapy and bevacizumab treatments in glioblastoma multiforme: A case series and review of the literature

KERTMEN N., KAVGACI G., Koc I., PARLAK SAĞOL Ş., IŞIKAY A. İ., YAZICI G.
ONCOLOGY LETTERS , sa.3, 2025 (SCI-Expanded, Scopus) identifier identifier

7. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases

KERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.
CANCER CONTROL , 2025 (SCI-Expanded, Scopus) identifier identifier

8. Prevalence of Hypertension and Blood Pressure Control in Familial Mediterranean Fever Patients

KAVGACI G., YETER H. H., ÜZERK KİBAR M., YILDIRIM T., Peynircioglu B. B., YILMAZ Ş. R., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , sa.1, 2025 (SCI-Expanded, Scopus) identifier

9. Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer

KAVGACI G., ŞAHİN T. K., Muderrisoglu T., Ileri S., GÜVEN D. C., AKSOY S.
EXPERT REVIEW OF ANTICANCER THERAPY , sa.12, ss.1319-1326, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

10. Ribociclib-induced autoimmune-like hepatitis: a case report

KAVGACI G., ŞAHİN T. K., SÖKMENSÜER C., BALABAN H. Y., AKSOY S.
JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

11. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.
MEDICINE , cilt.103, sa.30, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

12. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.
PHARMACEUTICALS , cilt.17, sa.7, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

13. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.
SUPPORTIVE CARE IN CANCER , cilt.32, sa.7, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

14. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer

KAVGACI G., Dizdar O., Yalcin S.
Anti-cancer drugs , cilt.35, sa.5, ss.459-461, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

15. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review

GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., et al.
ONCOLOGIST , cilt.29, 2024 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

16. Acute heart failure following pazopanib treatment: a literature review featuring two case reports

KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.
Anti-Cancer Drugs , cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

17. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sanci P. C., Guliyev M., et al.
Journal of Chemotherapy , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

18. Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report

KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.
PLASMATOLOGY , cilt.18, 2024 (ESCI, Scopus) identifier identifier

19. Advances in the Early Detection of Hepatobiliary Cancers

YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.
Cancers , cilt.15, sa.15, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

20. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

21. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

22. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

23. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, 2021 (SCI-Expanded, Scopus) identifier

24. Implementation of clinical pharmacy practices in nephrology unit

Tecen K., ÜZERK KİBAR M., KAVGACI G., Bayraktar-Ekincioglu A., Demirkan K., YILDIRIM T., et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , cilt.40, sa.1, ss.281, 2018 (SCI-Expanded, Scopus) identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Implementation of clinical pharmacy practices in nephrology unit

TECEN YÜCEL K., ÜZERK KİBAR M., KAVGACI G., Ekincioğlu A., DEMİRKAN S. K., YILDIRIM T., et al.
46th symposium on clinical pharmacy Heidelberg,Germany, 9 - 11 Ekim 2017, (Özet Bildiri)
Metrikler

Yayın

25

Yayın (WoS)

20

Yayın (Scopus)

20

Atıf (WoS)

6

H-İndeks (WoS)

2

Atıf (Scopus)

3

H-İndeks (Scopus)

1

Açık Erişim

6
BM Sürdürülebilir Kalkınma Amaçları